Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of SENS-401 for sudden sensorineural hearing loss
MOH_2018-12-06_003665Phase 3Completed
- Sponsor
- Sensorion
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of arazasetron besylate in acute sensorineural hearing loss (5 arms), sponsored by Sensorion. Primary endpoint: Hearing loss efficacy at end of 4-week treatment period. Started Dec 2018; status: completed.
02
Drugs
arazasetron besylate
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on MOH_2018-12-06_003665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-06_003665.